Jardiance shows significant benefit in EMPA-KIDNEY trial

4 November 2022

Further adding to the wealth of support for their blockbuster diabetes drug Jardiance (empagliflozin), German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) today released new data supporting its benefits in chronic kidney disease during the American Society of Nephrology (ASN)’s Kidney Week 2022.

The EMPA-KIDNEY Phase III clinical trial met its primary endpoint, demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with empagliflozin, the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo (HR; 0.72; 95% CI 0.64 to 0.82; p<0.000001; 3.8% absolute risk reduction).

The results were also published simultaneously in The New England Journal of Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK